-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Oncorus, Inc. (NASDAQ:ONCR) Short Interest Up 20.7% in November
Oncorus, Inc. (NASDAQ:ONCR) Short Interest Up 20.7% in November
Oncorus, Inc. (NASDAQ:ONCR – Get Rating) saw a large increase in short interest in the month of November. As of November 15th, there was short interest totalling 852,400 shares, an increase of 20.7% from the October 31st total of 706,200 shares. Currently, 4.8% of the shares of the company are sold short. Based on an average daily volume of 77,100 shares, the days-to-cover ratio is presently 11.1 days.
Institutional Investors Weigh In On Oncorus
A number of institutional investors have recently added to or reduced their stakes in the business. Millennium Management LLC bought a new stake in Oncorus during the 2nd quarter worth approximately $476,000. Renaissance Technologies LLC grew its holdings in Oncorus by 23.9% during the 2nd quarter. Renaissance Technologies LLC now owns 217,450 shares of the company's stock worth $274,000 after acquiring an additional 41,918 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in Oncorus by 106.6% during the 1st quarter. Bank of New York Mellon Corp now owns 122,047 shares of the company's stock worth $218,000 after acquiring an additional 62,985 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Oncorus by 35.1% in the 2nd quarter. Goldman Sachs Group Inc. now owns 117,925 shares of the company's stock worth $148,000 after purchasing an additional 30,668 shares during the period. Finally, Private Advisor Group LLC lifted its position in shares of Oncorus by 28.9% in the 2nd quarter. Private Advisor Group LLC now owns 81,304 shares of the company's stock worth $103,000 after purchasing an additional 18,220 shares during the period. 65.89% of the stock is owned by institutional investors.
Get Oncorus alerts:Wall Street Analysts Forecast Growth
ONCR has been the topic of several research reports. Piper Sandler downgraded shares of Oncorus from an "overweight" rating to a "neutral" rating and dropped their price objective for the stock from $6.00 to $2.00 in a report on Wednesday. Chardan Capital downgraded shares of Oncorus from a "buy" rating to a "neutral" rating in a report on Wednesday.
Oncorus Price Performance
Shares of Oncorus stock opened at $0.46 on Friday. The company has a quick ratio of 4.97, a current ratio of 4.97 and a debt-to-equity ratio of 0.24. The firm's 50 day moving average is $0.69 and its 200 day moving average is $1.11. Oncorus has a 1 year low of $0.41 and a 1 year high of $6.08.About Oncorus
(Get Rating)
Oncorus, Inc, a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers.
Featured Articles
- Get a free copy of the StockNews.com research report on Oncorus (ONCR)
- Why CSL Ltd Stock Could Be Worth a Look
- MarketBeat: Week in Review 11/28 – 12/02
- Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
- Institutions Are Buying Ambarella, Should You?
- Can ZIM Defy Broad Downturn In The Container Shipping Industry?
Receive News & Ratings for Oncorus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncorus and related companies with MarketBeat.com's FREE daily email newsletter.
Oncorus, Inc. (NASDAQ:ONCR – Get Rating) saw a large increase in short interest in the month of November. As of November 15th, there was short interest totalling 852,400 shares, an increase of 20.7% from the October 31st total of 706,200 shares. Currently, 4.8% of the shares of the company are sold short. Based on an average daily volume of 77,100 shares, the days-to-cover ratio is presently 11.1 days.
安可乐斯公司(纳斯达克代码:ONCR-GET Rating)在11月份见证了空头股数的大幅增长。截至11月15日,空头股数共有85.24万股,比10月31日的70.62万股增加了20.7%。目前,该公司4.8%的股份被卖空。根据日均成交量77,100股计算,目前天数与回补比率为11.1天。
Institutional Investors Weigh In On Oncorus
机构投资者看好Oncorus
A number of institutional investors have recently added to or reduced their stakes in the business. Millennium Management LLC bought a new stake in Oncorus during the 2nd quarter worth approximately $476,000. Renaissance Technologies LLC grew its holdings in Oncorus by 23.9% during the 2nd quarter. Renaissance Technologies LLC now owns 217,450 shares of the company's stock worth $274,000 after acquiring an additional 41,918 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in Oncorus by 106.6% during the 1st quarter. Bank of New York Mellon Corp now owns 122,047 shares of the company's stock worth $218,000 after acquiring an additional 62,985 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Oncorus by 35.1% in the 2nd quarter. Goldman Sachs Group Inc. now owns 117,925 shares of the company's stock worth $148,000 after purchasing an additional 30,668 shares during the period. Finally, Private Advisor Group LLC lifted its position in shares of Oncorus by 28.9% in the 2nd quarter. Private Advisor Group LLC now owns 81,304 shares of the company's stock worth $103,000 after purchasing an additional 18,220 shares during the period. 65.89% of the stock is owned by institutional investors.
一些机构投资者最近增持或减持了该业务的股份。Millennium Management LLC在第二季度购买了Oncorus的新股份,价值约476,000美元。复兴科技有限责任公司在第二季度增持了23.9%的Oncorus股份。复兴科技有限责任公司在上个季度增持了41,918股后,现在拥有217,450股该公司股票,价值27.4万美元。纽约梅隆银行(Bank Of New York Mellon Corp)在第一季度增持了106.6%的安可乐斯股份。纽约梅隆银行(Bank Of New York Mellon Corp)目前持有122,047股该公司股票,价值21.8万美元,此前该公司在上一季度增持了62,985股。高盛股份有限公司在第二季度将其在Oncorus股票的持仓量提高了35.1%。高盛股份有限公司在此期间增持了30,668股,目前持有117,925股该公司股票,价值148,000美元。最后,Private Advisor Group LLC在第二季度将其在Oncorus股票的持仓提高了28.9%。Private Advisor Group LLC在此期间额外购买了18,220股票,现在拥有81,304股该公司股票,价值103,000美元。65.89%的股份由机构投资者持有。
Wall Street Analysts Forecast Growth
华尔街分析师预测经济增长
ONCR has been the topic of several research reports. Piper Sandler downgraded shares of Oncorus from an "overweight" rating to a "neutral" rating and dropped their price objective for the stock from $6.00 to $2.00 in a report on Wednesday. Chardan Capital downgraded shares of Oncorus from a "buy" rating to a "neutral" rating in a report on Wednesday.
ONCR已经成为几份研究报告的主题。派珀·桑德勒在周三的一份报告中将Oncorus的股票评级从“增持”下调至“中性”,并将该股的目标价从6.00美元下调至2.00美元。Chardan Capital周三在一份报告中将Oncorus的股票评级从买入下调至中性。
Oncorus Price Performance
Oncorus性价比
About Oncorus
关于Oncorus
(Get Rating)
(获取评级)
Oncorus, Inc, a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers.
Oncorus,Inc.是一家临床阶段的生物制药公司,专注于为癌症患者开发病毒免疫疗法。该公司的主要候选产品是ONCR-177,这是一种肿瘤内注射的病毒免疫疗法,基于其溶瘤的单纯疱疹病毒1型平台,该平台正处于治疗各种癌症的I期临床试验。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on Oncorus (ONCR)
- Why CSL Ltd Stock Could Be Worth a Look
- MarketBeat: Week in Review 11/28 – 12/02
- Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
- Institutions Are Buying Ambarella, Should You?
- Can ZIM Defy Broad Downturn In The Container Shipping Industry?
- 免费获取StockNews.com关于Oncorus的研究报告(ONCR)
- 为什么CSL有限公司的股票值得一看
- MarketBeat:回顾一周11/28-12/02
- Okta Inc.庆祝收益节节攀升,但他们能持续这种提振吗?
- 机构正在购买安巴雷拉,你应该吗?
- ZIM能否抵御集装箱航运业的普遍低迷?
Receive News & Ratings for Oncorus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncorus and related companies with MarketBeat.com's FREE daily email newsletter.
接受Oncorus Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Oncorus和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧